Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Go back to Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome| (NASDAQ: NGNE) | Delayed: 32.09 -0.32 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.41 | 52 Week High | $ | |||
| Open | $32.49 | 52 Week Low | $ | |||
| Day High | $33.15 | P/E | N/A | |||
| Day Low | $31.86 | EPS | $ | |||
| Volume | 1,388,879 | |||||
